论文部分内容阅读
目的评价血清恶性肿瘤特异性生长因子(Tumor Supplied Group of Factors,TSGF)在肺癌诊断中的价值。方法对62例临床诊断为肺癌,35例肺良性病变(BPD)患者治疗前后血清TSGF的检测,并与40例正常人对照。结果肺癌组TSGF为(83.36±16.62)U/ml,阳性率85.5%,与BPD组及正常对照组比较差异有统计学意义(P<0.01);BPD组治疗前与正常对照组差异有统计学意义(P<0.01);BPD组抗炎治疗2周后与正常对照组比较差异无统计学意义。结论 TSGF作为新型的肿瘤标志物对肺癌的诊断具有广谱性、敏感性、特异性、准确性较高,它在肺癌的辅助诊断中有一定价值。
Objective To evaluate the value of Tumor Supplied Group of Factors (TSGF) in the diagnosis of lung cancer. Methods The serum levels of TSGF in 62 patients with lung cancer and 35 patients with benign lung disease (BPD) before and after treatment were measured and compared with 40 normal controls. Results The TSGF of the lung cancer group was (83.36 ± 16.62) U / ml, the positive rate was 85.5%, which was significantly different from that of the BPD group and the normal control group (P <0.01). There was significant difference between the BPD group and the normal control group (P <0.01). There was no significant difference between the BPD group and the normal control group after 2 weeks of anti-inflammatory treatment. Conclusion As a new tumor marker, TSGF has broad spectrum sensitivity, specificity and accuracy in the diagnosis of lung cancer. It has certain value in the diagnosis of lung cancer.